Find a Product

Webinars & Online Seminars

An online learning resource

DiscoverX offers a number of upcoming and previously recorded webinars, recorded online meetings and presentations with our scientists that cover a variety of relevant topics, tools and data analysis techniques.

 
<September 2017>
SunMonTueWedThuFriSat
27
 
28
 
29
 
30
 
31
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
BioMAPが今アツイ! 医療抗体などが騒がれている中で、低分子化合物も活躍?!
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
Webinar: Create Your Own Cell-Based A...
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
Event Date ▼ Event Name PDF Link Webinar Link
September 20, 2017 Webinar: Create Your Own Cell-Based Assays to Study Receptor Tyrosine Kinase Function - 30 min.

What will be covered?

  • RTK biology and drug discovery importance
  • Tools needed to create your own RTK cell lines and assays
  • Experimental design and workflows
  • Applications of RTK and related cell-based assays
Login to view Login to view
September 8, 2017 BioMAPが今アツイ! 医療抗体などが騒がれている中で、低分子化合物も活躍?! - 60 min.

What will be covered?

  • 世界で唯一:プライマリー細胞を使用した、ガンの微小細胞環境モデル
  • 話題となっている免疫チェックポイント阻害剤の評価例
  • 医療抗体の中でも低分子化合物が活躍?
  • BioMAPシステムの応用例
Login to view Login to view
August 16, 2017 Webinar: Discovery of Bacterial Effectors in the Human Microbiome and Isolation of a GPCR G2A/GPR132 Agonist - 30 min.

What will be covered?

  • The role of GPCRs in regulating host-microbial interactions
  • How to identify microbial metabolites that modulate GPCR functions
  • A case study on defining host-microbial interaction and therapeutic potential of N-acyl amides, bacterial metabolites that activate GPR132/G2A
Login to view Login to view
June 27, 2017 Webinar: Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells - 55 min.

What will be covered?

  • Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
  • Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
  • Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells
Login to view Login to view
May 19, 2017 SAFETYscan: オフターゲット効果を機能アッセイで同定,GPCR・チャネル・キナーゼ等を一気にスクリーニング - 60 min.

What will be covered?

  • 全てのヒトのターゲットで安全性を確認
  • 通常の結合データを上回る機能データ
  • アッセイ開発のコストと時間を削減
  •  
Login to view Login to view
May 18, 2017 Create Your Own Cellular Target Engagement Assay - 30 min.

What will be covered?

  • Overview of compound-target engagement
  • Tools and workflow to create your own cell-based target engagement assay
  • Applications of InCELL Pulse assays
Login to view Login to view
April 19, 2017 Webinar: Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing - 40 min.

What will be covered?

  • Using phenotypic profiling to characterize clinically successful drugs for a given indication
  • Combining target-based and phenotypic data to prioritize drugs for repurposing
  • Understanding how multi-targeted kinases can be pivoted towards new indications
Login to view Login to view
April 5, 2017 Webinar: From Chemistry to Clinic: Discovery of Biased Apelin Receptor Agonists and Action in the Cardiovascular System - 55 min.

What will be covered?

  • Role of GPCRs in human cardiovascular system
  • Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
  • Identifying biased agonists using pharmacologically-relevant functional cell based assays
  • Validating assays and minimizing inter-assay variation
Login to view Login to view
March 29, 2017 Webinar: Creating Cellular Target Engagement Assays for Diverse Kinases Using InCELL Pulse™ - 30 min.

What will be covered?

  • Overview of compound-target engagement and InCELL Pulse platform
  • Kinase drug discovery importance
  • Tools and workflow needed to create your own target engagement assay
  • Validation data showing several examples of diverse kinases
Login to view Login to view
March 10, 2017 免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.

What will be covered?

  • 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
  • PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
  • 放射性同位体を使用しないADCC(抗体依存性細胞傷害)の評価系
  •  
Login to view Login to view
March 9, 2017 Webinar: Mu Opioid Receptor Splicing and Signaling: Another Dimension of GPCR Function - 55 min.

What will be covered?

  • Overview of the mu opioid receptor signaling
  • GPCR splicing, using OPRM1 as an example
  • Region and cell specific splicing
  • Functional consequences of 5’ splicing
  • Functional consequences of 3’ splicing
Login to view Login to view
February 1, 2017 Webinar: Unlocking GPCRs for Oncology - 35 min.

What will be covered?

  • Opportunities and challenges for targeting GPCRs in oncology
  • Examples of GPCR-targeting investigational therapies for oncology
  • Imipridones, selective GPCR-targeting small molecules, that are in preclinical and clinical development for oncology
Login to view Login to view
December 7, 2016 Webinar: The Interplay of Kinase Broad Profiling and Phenotypic Screening - 60 min.

What will be covered?

  • Learn about the significance of kinase broad profiling and phenotypic screening on early kinase drug discovery
  • Learn how to design a kinase inhibitor broad profiling project and how the chemo-bioinformatic analysis can impact target deconvolution after phenotypic screening
Login to view Login to view
November 30, 2016 Webinar: Create Your Own InCELL Pulse™ Cellular Compound-Target Engagement Assay - 60 min.

What will be covered?

  • Overview of compound-target engagement
  • Tools needed to create your own target engagement assay
  • Experimental design and workflow
  • Applications of InCELL Pulse assays
Login to view Login to view
November 9, 2016 Webinar: Duplexed Screening of GPCRs to Measure Calcium and β-Arrestin - 60 min.

What will be covered?

  • Screening approaches for GPCR drug discovery
  • Creating a duplexed assay to monitor calcium and β-arrestin in a single well
  • Determine potential bias for various drugs and define potency ranking
Login to view Login to view
October 26, 2016 Webinar: Target to Phenotype: Tools to Accelerate Your Immuno-Oncology Drug Pipeline - 60 min.

What will be covered?

  • Challenges in immuno-oncology drug development
  • Tools to expedite and simplify any immuno-oncology drug development pipeline
Login to view Login to view
September 30, 2016 Webinar: Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models - 60 min.

What will be covered?

  • Overview of the BioMAP® immuno-oncology/oncology systems
  • Information BioMAP iOnc studies provide
  • Host stromal/vascular - tumor microenvironment biology
  • Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds
Login to view Login to view
September 9, 2016 DiscoverX:常に進化を続けている創薬・新薬開発市場への支援 - 60 min.

What will be covered?

  • 2016の創薬市場:「スマート」になった現在の薬剤
  • チェックポイント阻害剤の評価系・インターロイキン受容体・GPCR等
  • キナーゼ阻害剤・エピジェネティック阻害剤・PPI創薬のスクリーニング
  • 候補薬剤の表現型プロファイリング
Login to view Login to view
August 10, 2016 Webinar: New Tricks for Old Drugs: An Unbiased Phenotypic Approach to Drug Repurposing - 40 min.

What will be covered?

  • Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
  • Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
  • Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications
Login to view Login to view
July 27, 2016 Webinar: Understand Safety and Selectivity of Drug Candidates Before Expensive Animal Studies - 60 min.

What will be covered?

  • How PathHunter® GPCR Screening and Profiling Services can be used to triage hits, rank order compounds, and develop novel biased ligands
  • Tools to understand the mechanism of action of your drugs and their mode of action
  • How a case study of clinically approved drugs in our broad range of GPCR assays can be used to predict the selectivity and safety of your drug candidates
Login to view Login to view
July 20, 2016 Webinar: Introduction to KINOMEscan: Broad Applications to Drive Drug Discovery - 60 min.

What will be covered?

  • Overview of the KINOMEscan assay technology
  • Application of the KINOMEscan platform for selectivity and potency optimization
  • Development of chemical probes for understudied kinases
Login to view Login to view
June 29, 2016 Webinar: Building Relevant Cell-Based Assays for Co-Stimulatory and Co-Inhibitory Checkpoint Receptors - 60 min.

What will be covered?

  • Novel cell-based assays for checkpoint signaling receptors
  • Functional assays for biologics and small molecule screening
  • Applications for QC lot release testing of biologics
  • Assays for CD137, CTLA-4, TIGIT, PD-1, OX-40, CD40, TWEAK, TIM3, and VISTA
  • Custom assay development for novel checkpoint targets
Login to view Login to view
June 17, 2016 データまで二週間:キナーゼ・ブロモドメイン・アポトーシス阻害剤を評価 - 60 min.

What will be covered?

  • KINOMEscanアッセイ原理の詳細:結合系と機能系を比較
  • 新規キナーゼ標的:CDK10, CDK12, CDK20, MLKL and MLKL (full length), IRAK2 等
  • 40種類ものブロモドメインに対する阻害剤を評価
  • アポトーシス阻害剤の同定:BCL2scan
  • scanMAX報告書から得られる、裏データ・裏情報のご紹介
Login to view Login to view
June 15, 2016 Webinar: Make Your Own Cell-Based Assays to Study β-Arrestin Recruitment - 30 min.

What will be covered?

  • Overview of β-arrestin biology
  • Tools needed to create your own β-arrestin cell lines and assays
  • Experimental design and workflows
  • Applications of β-arrestin cell-based assays for GPCRs
Login to view Login to view
June 1, 2016 Webinar: Specifically Measure Target Cell Death for ADCC, ADCP, BiTe-like Bispecifics, and CAR-T - 45 min.

What will be covered?

  • Simple cell-based assays to measure target cell cytotoxicity in a co-culture
  • Assays for ADCC, ADCP, bi-specific antibody mediated T-cell redirection, and adoptive T-cell therapies such as CAR-T
  • Enabling technology to drive a cancer immunotherapy drug through the discovery and development pipeline
Login to view Login to view
May 25, 2016 Webinar: A Phenotypic Platform for Characterization of Drug Safety Mechanisms in Human Primary Cell Disease Models - 40 min.

What will be covered?

  • How to maximize knowledge of your compounds using the BioMAP® Diversity PLUS™ panel of human primary cells systems
  • How to understand mechanism classification analysis and toxicity signatures
  • A case study on discovery of a mechanism-based novel signature for skin irritation
Login to view Login to view
May 19, 2016 Webinar: Ready-to-use Potency Assays for Anti-VEGF Drugs Like Bevacizumab, Ranibizumab & Aflibercept - 60 min.

What will be covered?

  • Creation of cell-based bioassays for potency and stability testing
  • Application, development and validation of assays with drug molecule
  • Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
  • Qualified assays for > 30 biosimilars
Login to view Login to view
May 12, 2016 Webinar: Latest Trends in Ligand Bias and Allosteric Modulators – New Opportunities, Insights and Prospects for Cure - 60 min.

What will be covered?

  • Capabilities overview of LeadHunter Discovery Services
  • Identifying, characterizing and quantifying novel biased ligands using LeadHunter Services
  • Multiple pathways including ß-Arrestin and how biased signaling can influence efficacy in vivo
Login to view Login to view
April 22, 2016 BioMAP表現型プロファイリング:今まで見えなかった試験物質の一面を明瞭に - 60 min.

What will be covered?

  • Tofacitinibの様な抗炎症剤から、食材までの表現型解析例の紹介
  • 臨床試験への架け橋となったデータの実施例
  • Skin Rash・Thrombosis等を明瞭に:BioMAPシステムの応用例
  • パワーアップした試験報告書のご紹介:さらに充実したデータのご提供
  • メカニズム探査によるリード化合物の毒性、薬理、安全性等の同定
Login to view Login to view
April 20, 2016 Webinar: Identify Compounds that Rescue Disease Relevant Mutant Membrane Proteins - 30 min.

What will be covered?

  • Overview of membrane protein trafficking and protein misfolding diseases
  • Assay technology to simplify monitoring of protein trafficking
  • Screening for pharmacological chaperones
Login to view Login to view
March 30, 2016 Webinar: Enabling Development of Cancer Immunotherapy Drugs – From Discovery to Combination Strategies - 60 min.

What will be covered?

  • Simple cell-based assays for checkpoint signaling receptors
  • Assays with human primary cells in co-culture recreating the human tumor microenvironment
  • Enabling technologies to move an immune-oncology drug along the discovery and development pipeline
  • Drugs targeting PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
Login to view Login to view
March 25, 2016 免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.

What will be covered?

  • 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
  • PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
  • 放射性同位体を使用しないADCC(抗体依存性細胞傷害)の評価系
Login to view Login to view
March 16, 2016 KINOMEscan Profiling Services Webinar: Efficient Design and Interpretation of KINOMEscan Experiments: A Driver for All Stages of Drug Development - 60 min.

What will be covered?

  • Application of KINOMEscan technology for selectivity and potency optimization of your lead molecules
  • Design scanMAX, KdELECT or scanELECT experiments
  • Improved flexibility of custom panels for hit identification, hit to lead, SAR and lead optimization
  • 20 new kinase assays launched in 2016
Login to view Login to view
February 17, 2016 Biologics Webinar: Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors - 60 min.

What will be covered?

  • Novel cell-based assays for checkpoint signaling receptors
  • PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
  • Functional assays for biologics and small molecule screening
  • Applications for QC lot release testing of biologics
Login to view Login to view
September 24, 2015 Ligand Bias Simplified - A Novel Pharmacologic Toolbox - 30 min.

What will be covered

  • Capabilities overview of LeadHunter Discovery Services
  • How LeadHunter can be used to identify, characterize and quantify novel biased ligands
  • Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo
Login to view Login to view